title: [Combination of trastuzumab, aromatase inhibitor and anti-cancer drugs obtained a good prognosis for an inoperable stage III B breast cancer patient with giant skin ulceration].
abstract: A 68-year-old woman who had an inoperable, ER-positive, PgR-positive and HER2-positive advanced breast cancer with giant skin ulceration has been treated with the combination of trastuzumab, aromatase inhibitor and anti-cancer drugs. She was thus well-controll for over 9 years. Trastuzumab was administered more than 400 times, but no cardiac toxicity has been observed. The synergistic efficacy of the combination of trastuzumab and anti-cancer drugs was already proven, but it has recently been reported that concurrent treatment of trastuzumab and endocrine therapy improves the prognoses of triple positive breast cancer patients.
authors.affiliation: Breast Oncology Center, Double-Barred Cross Hospital, Japan Anti-Tuberculosis Association.
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Takeda
authors.forename: Noriyoshi
authors.initials: N
authors.lastname: Tanaka
authors.forename: Juichiro
authors.initials: J
authors.lastname: Konishi
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D011379:Prognosis; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D000068878:Trastuzumab; D014456:Ulcer / Q000209:etiology*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D047072:Aromatase Inhibitors; D000068878:Trastuzumab